Vantage logo

Is valrox dead?

Valrox leaves a disproportionate hole in Biomarin’s valuation, but gene therapy competitors shouldn’t celebrate just yet.

Vantage logo

The dream is over for Intercept

The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.

Vantage logo

Safety scare knocks Novartis

Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.